Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

3.44
-0.3200-8.51%
Post-market: 3.470.0300+0.87%19:57 EDT
Volume:1.21M
Turnover:4.34M
Market Cap:255.35M
PE:-2.83
High:3.80
Open:3.78
Low:3.44
Close:3.76
Loading ...

Buy Rating for Perspective Therapeutics: Clinical Advancements and Strategic Developments Drive Positive Outlook

TIPRANKS
·
25 Jun

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
23 Jun

B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating

MT Newswires Live
·
23 Jun

Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data

TIPRANKS
·
23 Jun

Perspective Therapeutics commences recruitment for 212PbVMT-alpha-NET

TIPRANKS
·
23 Jun

Perspective Therapeutics Commences Recruitment for [212PB]Vmt-Α-Net in the Third Dose Escalation Cohort of Its Ongoing Phase 1/2a Clinical Trial

THOMSON REUTERS
·
21 Jun

LifeSci Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
07 Jun

Perspective Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
03 Jun

RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Jun

Perspective Therapeutics Inc : RBC Raises Target Price to $16 From $15

THOMSON REUTERS
·
03 Jun

Promising Clinical Updates and Strong Safety Profile Support Buy Rating for Perspective Therapeutics

TIPRANKS
·
02 Jun

Perspective Therapeutics (CATX) Gets a Buy from Truist Financial

TIPRANKS
·
02 Jun

Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
01 Jun

Perspective Therapeutics Reports Promising Trial Results for [212Pb]VMT-α-NET

TIPRANKS
·
31 May

Perspective Therapeutics Highlights Updated Interim Data From Its Ongoing Phase 1/2a Clinical Trial of [212PB]Vmt-Α-Net at the 2025 Asco Annual Meeting

THOMSON REUTERS
·
31 May

Perspective Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
29 May

Buy Rating on Perspective Therapeutics: Promising Clinical Data, Strategic Advancements, and Strong Financial Position

TIPRANKS
·
27 May

Perspective Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
15 May

Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating

MT Newswires Live
·
14 May

Perspective Therapeutics Inc : Jonestrading Cuts Target Price to $18 From $21

THOMSON REUTERS
·
13 May